Retatrutide is a triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. Supports metabolism, energy use, and weight loss. Now in Phase 3 clinical trials by Eli Lilly and Company (LLY).
Molecular Weight: ~4119 g/mol
CAS: 2759019-86-6
Purity: ≥99%
For research purposes only.
Retatrutide is a triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. Supports metabolism, energy use, and weight loss. Now in Phase 3 clinical trials by Eli Lilly and Company (LLY).
Molecular Weight: ~4119 g/mol
CAS: 2759019-86-6
Purity: ≥99%
For research purposes only.
